Zobrazeno 1 - 10
of 388
pro vyhledávání: '"F, Latteri"'
Autor:
F. Salomone, I. Cacciola, S. Petta, V. Calvaruso, A. Micek, S. Madonia, M. Grova, M. Distefano, M. Cannavò, M.A. Di Rosolini, A. Digiacomo, F. Di Lorenzo, G. Bertino, A. Licata, F. Latteri, F. Benanti, A. Averna, L. Guarneri, I. Scalisi, C. Iacobello, A. Montineri, P. Colletti, F. Cartabellotta, A. Davì, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, A. Craxì, V. Di Marco
Publikováno v:
Digestive and Liver Disease. 54:S55-S56
Autor:
F. Latteri, Giuseppina Valeria Albanese, Marco Aiello, Nunzio Restuccia, Nicola Battelli, Hector Soto Parra, Francesco Verderame, Sabrina Paratore, Matteo Santoni, Paolo Bruzzi, Cinzia Solinas
Publikováno v:
Frontiers in oncology, 10
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Background: We hypothesized that non-small cell lung cancer (NSCLC) patients with a tumor positive for single nucleotide polymorphisms (SNPs) of the Excision Repair Cross Complementation Group 1 (ERCC-1) gene could be more genetically instable and co
Autor:
Francesco Verderame, Vito Barbieri, Hector Soto Parra, Annamaria Catino, Francesco Ferraù, Rossana Avola, Marco Aiello, Francesca Spinnato, F. Latteri, Lucia Gozzo, Oriana Valerio, Enrica Capelletto, Laura Noto, Domenico Galetta, Maria Rita Migliorino, Pierfrancesco Tassone, A.M. Morelli, Silvia Novello, Serena Ricciardi
Publikováno v:
Journal of Clinical Oncology. 39:e21116-e21116
e21116 Background: Osimertinib (OSI) is a potent irreversible EGFR TKI approved for 1st line therapy advanced EGFR+ NSCLC and for 2nd line T790M+ pts. The AURA trial showed promising results even in pts with T790M- NSCLC after no immediate prior OSI
Autor:
I. Cacciola, S. Petta, M. Distefano, M.R. Cannavò, A. Davì, S. Madonia, V. Calvaruso, L. Larocca, F. Di Lorenzo, A. Digiacomo, G. Bertino, A. Licata, F. Latteri, F. Benanti, R. Volpes, L. Guarneri, A. Averna, I. Scalisi, C. Iacobello, P. Colletti, F. Cartabellotta, V. Portelli, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, A. Craxì, V. Di Marco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afbb11939c74911e2b7d306c1b5dac5
http://hdl.handle.net/20.500.11769/299461
http://hdl.handle.net/20.500.11769/299461
Autor:
Elisabetta Campagnoli, Marco Alloisio, Emanuela Morenghi, Giorgio Brambilla, Hector Soto Parra, Armando Santoro, F. Latteri, Raffaele Cavina, Walter Torri
Publikováno v:
Investigational New Drugs. 25:57-62
Three and 4-week cisplatin-gemcitabine schedules have shown similar dose-intensity (DI) and activity in non-small-cell lung cancer (NSCLC). The 3-week schedule is generally preferred because it enables better treatment compliance. To improve DI and c
Autor:
Marco Alloisio, Paolo Andrea Zucali, Raffaele Cavina, Armando Santoro, Maria Fazio, F. Latteri, Elisabetta Campagnoli, Hector Soto Parra, Fabio De Vincenzo, Giovanni Luca Ceresoli
Publikováno v:
Oncology. 71:229-236
Objectives: A dose-finding study of a new cisplatin/vinorelbine schedule was done to increase activity of the combination, and improve compliance of non-small-cell lung cancer patients. Methods: Beginning with cisplatin 40 mg/m2 on days 1, 2 and vino
Autor:
Emanuela Morenghi, Vittorio Pedicini, Marco Alloisio, Massimo Roncalli, Raffaele Cavina, Benvenuto Ferrari, Valeria Ginanni, Elisabetta Campagnoli, Gianni Ravasi, F. Latteri, Armando Santoro, H. Soto Parra, Paolo Andrea Zucali
Publikováno v:
Annals of Oncology. 15:33-37
Background: Gefitinib (Iressa™, ZD1839) is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Phase I studies showed that it is well tolerated, with evidence of tumor regression in patients with advanced
Autor:
Gianni Ravasi, H. Soto Parra, Raffaele Cavina, G. Antonelli, A. Sala, Marco Alloisio, Emanuela Morenghi, M. Dambrosio, F. Latteri, Armando Santoro
Publikováno v:
Annals of Oncology. 13:1080-1086
Background The cisplatin and gemcitabine (GC) regimen is usually administered as a 4- or 3-week schedule; however, the best schedule to use is still unclear. We therefore started a randomized phase II trial to compare toxicity and dose intensity (DI)
Autor:
Roberto Bordonaro, Pier Giorgio Petronini, Cristina Caffarra, Marcello Tiseo, P. Spadaro, Massimo Ippolito, Paolo Bruzzi, F. Latteri, Maura Scarlattei, Roberta Alfieri, Marco Bartolotti, Beatrice Bortesi, Claudia Fumarola, Andrea Ardizzoni, Sebastiano Cosentino, Hector Soto Parra, Andrea Cavazzoni, Livia Ruffini
Background: [18F]fluorodeoxyglucose (FDG)-PET is being evaluated as a tool for the early detection of response to various targeted agents in solid tumors. The aim of this study was to evaluate the predictive value of PET response after 2 days of erlo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40894ea81ef46555684c18e404d8268c
http://hdl.handle.net/20.500.11769/369769
http://hdl.handle.net/20.500.11769/369769
Autor:
H Soto Parra, A. Sala, Marco Alloisio, Antonella Santoro, F. Latteri, M. Dambrosio, Raffaele Cavina
Publikováno v:
Scopus-Elsevier